During the past few legislative sessions, Congress has been considering adoption of a regulatory pathway that would allow for FDA approval of "follow-on biologic" products, or "biosimilars." Questions surrounding the safety of such products, patent protection, and the length of data exclusivity periods lie at the heart of this debate. This teleconference reviews the key provisions of the most recent proposals for biosimilar legislation and the implications for the biotech industry if they become law.
Stay Up To Date with Ropes & Gray
Subscribe to Our Podcast
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Follow Us on Social
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
Join Our Mailing List
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.